Leverkusen – Chemicals group LANXESS is extending its activities in the area of insect repellents. LANXESS subsidiary Saltigo and the Italian company Endura SpA Fine Chemicals have signed a contract under whose terms Endura will market Saltigo’s active ingredient Bayrepel® (Icaridin) with immediate effect in Central and South America, Africa, the Middle East and India. “This is another milestone in our drive to market Bayrepel® all over the globe,” said Dr. Axel Westerhaus, Saltigo’s Managing Director.

To date, the world’s best known product based on Bayrepel® is Autan, a registered trademark of S.C. Johnson & Son, Inc., USA. In many countries across the world, dangerous diseases such as malaria, yellow fever and the West Nile virus are transmitted by mosquitoes and other insects. Bayrepel® supports the fight against these diseases and is recommended by the World Health Organization (WHO) as an active ingredient.

Only recently the active ingredient was also registered in Malaysia. In addition, Saltigo has also received the approval of the US Environmental Protection Agency (EPA) for two of its own formulas. The collaboration with Endura is now going to support product marketing in other important regions.

Saltigo is a technology-based, innovative globally operating company with particular expertise in the custom manufacturing of fine chemicals.  Products are exclusively manufactured according to the wishes and needs of the customer. Saltigo employs some 1,400 people at its sites in Leverkusen and Dormagen and achieved sales of approximately EUR about 400 million in 2005.

 Information for editors:

All our news releases and photos can be found on the LANXESS homepage at www.lanxess.com under the “Press” button. Any available visual material can also be downloaded from there.

Leverkusen,     March 9, 2007

ak              (2007-0032e)

Forward-looking statements

This news release contains forward-looking statements based on current assumptions and forecasts made by LANXESS AG management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.